{"name": "pSivida",
 "permalink": "psivida",
 "crunchbase_url": "http://www.crunchbase.com/company/psivida",
 "homepage_url": "http://www.psivida.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "(617) 926-5000",
 "description": "",
 "created_at": "Fri Jan 21 02:52:21 UTC 2011",
 "updated_at": "Mon Dec 03 05:03:09 UTC 2012",
 "overview": "\u003Cp\u003EpSivida Corp. develops drug delivery products that are administered by implantation, injection or insertion. Once administered, a drug is released on a controlled and level basis for months or years. The Company has two core technology systems, Durasert and BioSilicon. pSivida Corp. has one product candidate for chronic eye disease that has been given Priority Review by the United States Food and Drug Administration (FDA). It has a collaboration with Pfizer, Inc. (Pfizer) to develop additional ophthalmic products. Iluvien, the product candidiate with Priority Review, is designed to provide sustained release treatment for Diabetic Macula Edema (DME). Iluvien is licensed to Alimera Sciences, Inc (Alimera), which is completing fully-recruited Phase III clinical trials. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       78],
      "assets/images/resized/0011/8304/118304v1-max-150x150.png"],
     [[204,
       107],
      "assets/images/resized/0011/8304/118304v1-max-250x250.png"],
     [[204,
       107],
      "assets/images/resized/0011/8304/118304v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Paul",
      "last_name": "Ashton",
      "permalink": "paul-ashton",
      "image": null}},
   {"is_past": false,
    "title": "Vice President, Finance",
    "person":
     {"first_name": "Len",
      "last_name": "Ross",
      "permalink": "len-ross",
      "image": null}},
   {"is_past": false,
    "title": "Vice President of Operations",
    "person":
     {"first_name": "Marty",
      "last_name": "Nazzaro",
      "permalink": "marty-nazzaro",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$40M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2012/07/16/daily71-pSivida-partner-to-get-40M-to-develop-Iluvien.html",
    "source_description": "pSivida partner to get $40M to develop Iluvien",
    "raised_amount": 40000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 7,
    "funded_day": 18,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "400 Pleasant Street",
    "address2": "",
    "zip_code": "02472",
    "city": "Watertown ",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "pSivida raising $11M financing",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 19,
    "source_url": "http://www.masshightech.com/stories/2011/01/17/daily23-pSivida-raising-11M-financing.html",
    "source_text": "",
    "source_description": "pSivida raising $11M financing",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "pSivida",
      "permalink": "psivida"}},
   {"description": "reports positive results from a 36-month trial of its Iluvien treatment for diabetic macular edema (DME), which affects some 1 million Americans",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 3,
    "source_url": "http://www.masshightech.com/stories/2011/01/31/daily51-Psivida-reports-positive-results-for-Iluvien-eye-treatment.html",
    "source_text": null,
    "source_description": "Psivida reports positive results for Iluvien eye treatment",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "pSivida",
      "permalink": "psivida"}},
   {"description": "breathing new life into off-patent drugs by using them with its miniaturized drug-delivery products, which deliver lower, time-released doses of therapies for longer periods",
    "stoned_year": 2011,
    "stoned_month": 2,
    "stoned_day": 3,
    "source_url": "http://www.masshightech.com/stories/2011/01/31/daily47-Psivida-eyes-opportunities-in-off-patent-drugs.html",
    "source_text": null,
    "source_description": "Psivida eyes opportunities in off-patent drugs",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "pSivida",
      "permalink": "psivida"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:PSDV"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}